KANSAS CITY, Kan.
July 23, 2013
/PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, will host a conference call and live audio webcast on
Tuesday, August 13, 2013
8:00 a.m. ET
to discuss its financial results for the quarter ended
June 30, 2013
, and to provide an update on its pet therapeutics development programs.
Interested participants and investors may access the conference call by dialing (800) 860-2442 (U.S.), (866) 605-3852 (
), or (412) 858-4600 (international). An audio webcast will be accessible via the Investors Relations section of the Aratana Therapeutics website
A replay of the call will be available for 90 days beginning at approximately
10:00 a.m. ET
, 2013. Access numbers for this replay are (877) 344-7529 (U.S./
) and (412) 317-0088 (international); conference ID: 10031855. The webcast replay will remain available in the Investors Relations section of the Aratana Therapeutics website for 90 days.
About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into regulatory-approved therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit
Tiberend Strategic Advisors, Inc.
, Ph.D. (Investors)
; (212) 375-2664
; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.